# **OFFICIAL**

APR.16.2004 1:07PM

NO.091 P.1



#### GENAISSANCE PHARMACEUTICALS

### RECEIVED GENTRAL FAX CENTER

APR 1 6 2004

FIVE SCIENCE PARK NEW HAVEN, CT 06511 TEL. 203.773,1450 FAX. 203.562.9377 WWW.GENAISSANCE,COM

To: Commissioner for Patents

Date: April 16, 2004

Company: U.S. Patent & Trademark Office

Pages: 5 (including cover sheet)

Fax Number: 703.872.9306

From: Eileen McCaughern

Subject: U.S, Appl. No. 09/936,499

Please see attached.

1:08PM

## **OFFICIAL**

## **GENTRAL FAX CENTER**

APR 1 6 2004

NO.091 P.2

PTQ/SB/64 (11-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)		Docket Number (Optional) MWH-0031US	
	First named inventor: Stephen B. Liggett		
	Application No.: 09/936,499	Art Unit: 1634	
	Filed: December 17, 2001	December 17, 2001 Examiner: Goldberg, J.A.	
	Title; VARIATION IN DRUG RESPONSE RELATED TO POLYMORPHISMS IN BETA 2-ADRENERGIC RECEPTOR		
	Attention: Office of Petitions  Mall Stop Petition  Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 FAX: (703) 308-6916  NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (703) 305-9282.		
	The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus an extensions of time actually obtained.		
•	APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION		
	NOTE: A grantable petition requires the following items;  (1) Petition fee;  (2) Reply and/or issue fee;  (3) Terminal disclaimer with disclaimer feerequired for all utility and plant applications filed before June 8, 1995; and for all design applications; and  (4) Statement that the entire delay was unintentional.		
1. Petition fee  Small entity-fee \$ (37 CFR 1.17(m)). Applicant claims small entity status, See 37 CFR 1.27.			
☑ Other than small entity - fee \$ 1350.00 (37 CFR 1.17(m))			
	2. Reply and/or fee  A. The reply and/or fee to the above-noted Office action in the form of has been filed previously on is enclosed herewith.  B. The issue fee and publication fee (if required) of \$ 1330.00 has been paid previously on is enclosed herewith.	·	tify type of reply):

[Page 1 of 2]

[Fage 1 of 2]
This collection of information is required by 37 CFR 1.137. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

NO.091 P.3

PTO/SB/64 (08-03)
Approved for use 07/31/2006, OMB 0851-0031
U.S. Patent and Tradomark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee				
☑ Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.				
☐ A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).				
filing of a grantable petition under 37 CF Trademark Office may require addition	the required reply from the due date for the required reply until the R 1.137(b) was unintentional. [NOTE. The United States Patent and nal information if there is a question as to whether either the lon under 37 CFR 1.137(b) was unintentional (MPEP			
	n may become public. Credit card information should not redit card information and authorization on PTO-2038.			
April 16, 2004	Vz			
Date	Signature			
Telephone	•			
Number 203,773,1450 Matthew M. Catlett, Registration No. 44,067				
	Typed or printed name			
	Genaissance Pharmaceuticals, Inc.			
	Address			
Enclosures: Fee Payment	Five Science Park, New Haven, CT 06511			
☐ Reply	Address			
☐ Terminal Disclaimer Form				
Additional sheets containing statements establishing unintentional delay				
Other: "Part B - Fee(s) Transmittar" (Reply to Notice of Allowance and Fee(s) Due)				
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]				
I hereby certify that this correspondence is being:				
deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.				
transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 300-6016.				
April 16, 2004	Ce Malan			
Date	Signature			
	()			
	Elleen McCaughern  Type or printed name of person signing certificate			
· · · · · ·	type of pinted nature of belacit affinition certificate			